Use of Buserelin depot, a gonadotropin-releasing hormone agonist, in the treatment of prostate cancer
https://doi.org/10.17650/2070-9781-2014-3-74-79
Abstract
Buserelin is one of the first synthetic gonadotropin-releasing hormone agonists. The R.M. Fronshtein Clinic of Urology, I.M. Sechenov First Moscow State Medical University, has experience in using Buserelin depot in 32 patients with metastatic prostate cancer. The results of using Buserelin depot for 12 months are described. There was a significant reduction in prostate-specific antigen levels in the entire group.
Twenty-seven (84.4 %) patients could achieve tumor stabilization. Twenty (62.5 %) of the 32 patients treated with Buserelin depot at the Clinic of Urology showed decreased residual urine; 9 (28.1%) had no changes and 3 (9.4 %) displayed increased residual urine. The administration of the drug caused significant bone pain relief in 76.5 % of the cases.
All the Buserelin depot-treated patients satisfactorily tolerated the given treatment. There was either concomitant disease progression or treatment discontinuation in none of the cases. Thus, Buserelin depot proved to be an effective drug with a good safety profile.
About the Authors
L. M. Rapoport
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
Russian Federation
Research Institute of Uronephrology and Human Reproductive Health; Department of Urology
Russian Federation
Research Institute of Uronephrology and Human Reproductive Health; Department of Urology
Yu. L. Demidko
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
Russian Federation
Research Institute of Uronephrology and Human Reproductive Health; Department of Urology
Russian Federation
Research Institute of Uronephrology and Human Reproductive Health; Department of Urology
References
1. Трапезникова М.Ф., Кушлинский Н.Е. Андрогены и антиандрогенная терапия рака предстательной железы. В кн.: Рак предстательной железы. Под ред. Н.Е. Кушлинского, Ю.Н. Соловьева, М.Ф. Трапезниковой. М.: Издательство РАМН, 2002.
2. Oefelein M.G., Feng A., Scolieri M.J. еt аl. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 2000;56(6):1021–4.
3. McLeod D.G. Hormonal therapy: historical perspective to future directions. Urology 2003;61(2 Suppl 1):3–7.
4. Heidenreich A., Bolla M., Joniau S. еt аl. Guidelines on Prostate Cancer. European Association of Urology, 2010.
5. Bruchovsky N. Comparison of the metabolites formed in rat prostate following the in vivo administration of seven natural androgens. Endocrinology 1971;89(5): 1212–22.
6. Radlmaier A., Bormacher K., Neumann F. Hot flushes: mechanism and prevention. Prog Clin Biol Res 1990;359:131–40.
7. Agarwal D.K., Costello A.J., Peters J. et al. Differential response of prostate specific antigen to testosterone surge after luteinizing hormone-releasing hormone analogue in prostate cancer and benign prostatic hypertrophy. BJU 2000;85(6):690–5.
8. Матвеев В.Б., Волкова М.И. Роль дегареликса (фирмагон) в лечении распространенного рака предстательной железы: можно ли улучшить качество кастрационной терапии? Онкоурология 2011;(1):66–71.
9. Сивков А.В. Матвеев В.Б., Бухаркин Б.В. и др. Результаты длительного применения агониста гонадотропин-рилизинг-гормона бусерелина-депо у больных раком предстательной железы. Consilium Мedicum 2005; 7(7):591–5.
10. Оха У.К., Логью Дж. Лечение рака простаты. В кн.: Рак простаты. Под ред. У.К. Оха, Дж Логью. М.: Рид Элсивер, 2009.
11. Geller J., Albert J., Vik A. Advantages of total androgen blockade in the treatment of advanced prostate cancer. Semin Oncol 1988;15(2 Suppl 1):53–61.
12. Labrie F., Dupont A., Belanger A. et al. New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate 1983;4(6):579–94.
13. Crawford E.D., Eisenberger M.A., McLeod D.G. et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321(7):419–24.
14. Воробьев А.В. Рак предстательной железы. В кн.: Лекции по фундаментальной и клинической онкологии. Под ред. В.М. Моисеенко, А.Ф. Урманичевой, К.П. Хансона. СПб.: Издательство Н-Л, 2004.
15. Yagoda A., Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993;71(3 Suppl):1098–109.
16. Isaacs J.T., Coffey D.S. Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res 1981;41(12 Pt 1):5070–5.
17. Anderson J. Does GnRH agonist + antiandrogen = GhRH bloker (antagonist)? Vienna, 2011.
18. Bruchovsky N., Rennie P.S., Coldman A.J. et al. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 1990;50(8):2275–82.
Review
For citations:
Rapoport L.M., Demidko Yu.L. Use of Buserelin depot, a gonadotropin-releasing hormone agonist, in the treatment of prostate cancer. Andrology and Genital Surgery. 2014;15(3):74-79. (In Russ.) https://doi.org/10.17650/2070-9781-2014-3-74-79
Views:
1495
JATS XML
Email this article 